Search

Your search keyword '"Engert, Andreas"' showing total 28 results
Start Over Author "Engert, Andreas" Journal leukemia & lymphoma
28 results on '"Engert, Andreas"'

1. AFM13 in patients with relapsed or refractory classical Hodgkin lymphoma: final results of an open-label, randomized, multicenter phase II trial

Author

Sasse, Stephanie, primary, Bröckelmann, Paul Jan, additional, Momotow, Jesko, additional, Plütschow, Annette, additional, Hüttmann, Andreas, additional, Basara, Nadezda, additional, Koenecke, Christian, additional, Martin, Sonja, additional, Bentz, Martin, additional, Grosse-Thie, Christina, additional, Thorspecken, Sven, additional, de Wit, Maike, additional, Kobe, Carsten, additional, Dietlein, Markus, additional, Tresckow, Bastian von, additional, Fuchs, Michael, additional, Borchmann, Peter, additional, and Engert, Andreas, additional

Published
2022
Full Text
View/download PDF

3. Volumetric assessment of mediastinal lymphoma masses in Hodgkin lymphoma

Author

Baues, Christian, primary, Görgen, Helen, additional, Semrau, Robert, additional, Nast-Kolb, Beatrix, additional, Assenmacher, Katja, additional, Celik, Eren, additional, Morgenthaler, Janis, additional, Rosenbrock, Johannes, additional, Trommer, Maike, additional, Houbois, Christian, additional, Kobe, Carsten, additional, Kriz, Jan, additional, Engert, Andreas, additional, and Marnitz, Simone, additional

Published
2019
Full Text
View/download PDF

5. Survivors' perspectives on risks and benefits of Hodgkin lymphoma treatment: results of a survey by the German Hodgkin Study Group.

Author

Kreissl, Stefanie, Goergen, Helen, Müller, Horst, Bürkle, Carolin, Fuchs, Michael, Engert, Andreas, Behringer, Karolin, Borchmann, Peter, Meissner, Julia, and Mehnert, Anja

Subjects
HODGKIN'S disease, LYMPHOMA treatment, THERAPEUTICS, FOLLOW-up studies (Medicine)
Abstract

We performed a survey in Hodgkin lymphoma survivors to learn more about their perspectives on treatment risks and benefits. We sent questions to 1149 survivors from the GHSG's HD13-15 trials with (N = 249) or without (N =900) documented progression or relapse. The participation rate was 52% (N =581). After median follow-up of 106 months, 40% of relapse-free and over 60% of relapsed survivors were still worried about late effects and the possibility of relapse. Chemotherapy, largely independent of its intensity, had been a strain on 74% of relapse-free and 90% of relapsed survivors. Most physical, psychological, and socio-economic sequelae were more frequent among relapsed survivors (p <.05) and described as very burdensome. 74% of relapse-free and 61% of relapsed survivors considered primary cure from Hodgkin lymphoma as the most important aspect in the choice of treatment. Accordingly, primary optimal lymphoma control is of utmost importance from the patients' perspective. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

8. Prognostic relevance of DHAP dose-density in relapsed Hodgkin lymphoma: an analysis of the German Hodgkin-Study Group

Author

Sasse, Stephanie, primary, Alram, Magdalena, additional, Müller, Horst, additional, Smardová, Lenka, additional, Metzner, Bernd, additional, Doehner, Hartmut, additional, Fischer, Thomas, additional, Niederwieser, Dietger W., additional, Schmitz, Norbert, additional, Schäfer-Eckart, Kerstin, additional, Raemaekers, John M. M., additional, Schmalz, Oliver, additional, Tresckow, Bastian V., additional, Engert, Andreas, additional, and Borchmann, Peter, additional

Published
2015
Full Text
View/download PDF

9. Panobinostat consolidation in patients with Hodgkin lymphoma at risk for relapse after high dose chemotherapy and autologous stem cell transplant: final results after early trial discontinuation.

Author

von Tresckow, Bastian, Morschhauser, Franck, Szer, Jeffrey, Eichenauer, Dennis A., Abramson, Jeremy S., Sureda, Anna, and Engert, Andreas

Subjects
HODGKIN'S disease treatment, ANTINEOPLASTIC agents, PLACEBOS, DRUG efficacy, TREATMENT effectiveness, CANCER relapse, CANCER chemotherapy, STEM cell transplantation
Abstract

The article discusses a study on the use of the oral deacetylase inhibitor panobinostat to treat patients with Hodgkin lymphoma. The study examined 27 patients who received panobinostat and 14 patients who were given placebos. The results revealed relapse in patients after they received high dose chemotherapy and underwent autologous stem cell transplants.

Published
2017
Full Text
View/download PDF

10. Outcome and risk factors of patients with Hodgkin Lymphoma who relapse or progress after autologous stem cell transplant

Author

von Tresckow, Bastian, primary, Müller, Horst, additional, Eichenauer, Dennis A., additional, Glossmann, Jan P., additional, Josting, Andreas, additional, Böll, Boris, additional, Klimm, Beate, additional, Sasse, Stephanie, additional, Fuchs, Michael, additional, Borchmann, Peter, additional, and Engert, Andreas, additional

Published
2014
Full Text
View/download PDF

11. Early thymus and activation-regulated chemokine (TARC) reduction and response following panobinostat treatment in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplant

Author

Harrison, Simon J., primary, Hsu, Andy K., additional, Neeson, Paul, additional, Younes, Anas, additional, Sureda, Anna, additional, Engert, Andreas, additional, Prince, H. Miles, additional, Li, Martha, additional, Savage, Paula, additional, Bugarini, Roberto, additional, Williams, Denise, additional, Squier, Margaret, additional, and Ritchie, David S., additional

Published
2013
Full Text
View/download PDF

12. Anti-epidermal growth factor receptor antibody cetuximab in refractory or relapsed multiple myeloma: a phase II prospective clinical trial

Author

von Tresckow, Bastian, primary, Boell, Boris, additional, Eichenauer, Dennis, additional, Beschorner, Denissa, additional, Knop, Stefan, additional, Goebeler, Maria-Elisabeth, additional, Chemnitz, Jens Marcus, additional, Hallek, Michael, additional, Engert, Andreas, additional, and Huebel, Kai, additional

Published
2013
Full Text
View/download PDF

14. Brentuximab vedotin (SGN-35) in patients with transplant-naive relapsed/refractory Hodgkin lymphoma

Author

Sasse, Stephanie, primary, Rothe, Achim, additional, Goergen, Helen, additional, Eichenauer, Dennis A., additional, Lohri, Andreas, additional, Kreher, Stephan, additional, Jäger, Ulrich, additional, Bangard, Christopher, additional, Kuhnert, Georg, additional, Böll, Boris, additional, von Tresckow, Bastian, additional, and Engert, Andreas, additional

Published
2013
Full Text
View/download PDF

15. Prognostic relevance of DHAP dose-density in relapsed Hodgkin lymphoma: an analysis of the German Hodgkin-Study Group.

Author

Sasse, Stephanie, Alram, Magdalena, Müller, Horst, Smardová, Lenka, Metzner, Bernd, Doehner, Hartmut, Fischer, Thomas, Niederwieser, Dietger W., Schmitz, Norbert, Schäfer-Eckart, Kerstin, Raemaekers, John M. M., Schmalz, Oliver, Tresckow, Bastian V., Engert, Andreas, and Borchmann, Peter

Subjects
HODGKIN'S disease treatment, DIHYDROXYACETONE phosphate, CANCER chemotherapy, CANCER relapse, HODGKIN'S disease, STEM cell transplantation, AUTOTRANSPLANTATION, PROGRESSION-free survival, PROGNOSIS
Abstract

Only 50% of patients with relapsed Hodgkin lymphoma (HL) can be cured with intensive induction chemotherapy, followed by high-dose chemotherapy (HDCT) and autologous stem cell transplant (ASCT). Based on the results of the HDR2 trial two courses of DHAP and subsequent HDCT/ASCT are the current standard of care in relapsed HL. In order to assess the prognostic relevance of DHAP dose density, we performed a retrospective multivariate analysis of the HDR2 trial (N = 266). In addition to four risk factors (early or multiple relapse, stage IV disease or anemia at relapse, and grade IV hematotoxicity during the first cycle of DHAP) a delayed start of the second cycle of DHAP > day 22 predicted a significantly poorer progression-free survival (PFS,p = 0.0356) and overall survival (OS,p = 0.0025). In conclusion, our analysis strongly suggests that dose density of DHAP has a relevant impact on the outcome of relapsed HL patients. [ABSTRACT FROM PUBLISHER]

Published
2016
Full Text
View/download PDF

21. Elevated pretreatment interleukin-10 serum level is an International Prognostic Score (IPS)-independent risk factor for early treatment failure in advanced stage Hodgkin lymphoma

Author

Rautert, Roger, primary, Schinköthe, Timo, additional, Franklin, Jeremy, additional, Weihrauch, Martin, additional, Böll, Boris, additional, Pogge, Elke, additional, Bredenfeld, Henning, additional, Engert, Andreas, additional, Diehl, Volker, additional, and Re, Daniel, additional

Published
2008
Full Text
View/download PDF

24. Early thymus and activation-regulated chemokine (TARC) reduction and response following panobinostat treatment in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplant.

Author

Harrison, Simon J., Hsu, Andy K., Neeson, Paul, Younes, Anas, Sureda, Anna, Engert, Andreas, Prince, H. Miles, Li, Martha, Savage, Paula, Bugarini, Roberto, Williams, Denise, Squier, Margaret, and Ritchie, David S.

Subjects
HEALTH outcome assessment, HODGKIN'S disease, STEM cell transplantation, CHEMOKINES, CYTOKINES, CANCER chemotherapy
Abstract

In a phase 2 trial of panobinostat in 129 patients with relapsed or refractory Hodgkin lymphoma, exploratory analyses of chemokines and cytokines were prospectively performed in 109 patients to determine their association with clinical outcomes. Patients were categorized into two groups (reductions > median and reductions ≤ median) based on percentage change from baseline of log10 transformed measurements. Thymus and activation-regulated chemokine (TARC) was most strongly associated with clinical outcome. Early reduction of TARC was observed in responding patients, with the greatest reduction at cycle 1, day 15 (C1D15). Of 93 patients with C1D15 samples, there were three complete and 25 partial responses. The group with TARC reductions > median at C1D15 had more responders (18 [39%] vs. 10 [21%]), longer progression-free survival (10.6 vs. 4.9 months), shorter time to response and longer overall survival than the group with reductions ≤ median. This study is registered at , NCT00742027. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

27. Carboxypeptidase-G[sub2] Rescue in Cancer Patients with Delayed Methotrexate Elimination after High-dose Methotrexate Therapy.

Author

Krause, Anke S., Wiehrauch, Martin R., Bode, Udo, Fleischhack, Gudrun, Elter, Thomas, Heuer, Theodor, Engert, Andreas, Diehl, Volker, and Josting, Andreas

Subjects
CANCER treatment, METHOTREXATE
Abstract

High-dose methotrexate (HDMTX) is a component of many cancer treatment regimens. Despite careful management, delayed renal clearance, followed by extremely high serum levels with potentially life- threatening toxicity can occur. In the present study, we report our results of carboxypeptidase-G[SUB2] (CPDG[SUB2]) rescue in 8 patients with delayed methotrexate elimination and renal impairment after HDMTX therapy for lymphoma or osteosarcoma. A dose of 50 U/kg CPDG[SUB2] was administered. MTX plasma levels decreased rapidly and recovery of renal function was observed in all patients. No patient developed severe WHO grade 4 MTX toxicity. CPDG[SUB2] provides an alternative route of MTX elimination by converting it to inactive and non-toxic metabolites. CPDG[SUB2] rescue was well tolerated, safe and very effective in preventing severe or life-threatening MTX toxicity. [ABSTRACT FROM AUTHOR]

Published
2002
Full Text
View/download PDF

28. Anti-epidermal growth factor receptor antibody cetuximab in refractory or relapsed multiple myeloma: a phase II prospective clinical trial.

Author

von Tresckow, Bastian, Boell, Boris, Eichenauer, Dennis, Beschorner, Denissa, Knop, Stefan, Goebeler, Maria-Elisabeth, Chemnitz, Jens Marcus, Hallek, Michael, Engert, Andreas, and Huebel, Kai

Subjects
CETUXIMAB, MULTIPLE myeloma treatment, DEXAMETHASONE, THERAPEUTICS
Abstract

A letter to the editor is presented in which the authors comment on a phase II prospective clinical trial concerning the use of cetuximab, an anti-epidermal growth factor receptor antibody, in treating refractory or relapsed multiple myeloma both on its own and combined with dexamethasone.

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results